drug discovery

AION Labs CEO, Mati Gill, discusses the company’s extensive backing from pharma and tech giants to build AI startups, and how AION is looking beyond AI to explore quantum technologies for research and development in drug discovery.

The funds will be used to bolster AI and computational physics-based model development for numerous modalities.

The company recently presented clinical data at the European Society for Medical Oncology Congress for an investigational drug that displayed anti-tumor activity and a good safety profile.

About 300 million prescription records were used to train the AI to reveal drug safety issues and opportunities for repurposing medicines.

The new firm will offer partners an expanded range of methods and workflows for small-molecule and peptide drug discovery.

The company unveiled TxGemma, a collection of Gemma-based open models aimed at improving the efficiency of AI-powered drug discovery, during its recent Check Up event.   

The company, in partnership with Microsoft, aims to develop cancer medicines, followed by treatments for autoimmune diseases and rare conditions.

The money will be used to develop new medications and biologicals.  

Tx-LLM was fine-tuned from Google's Med-PaLM 2 and created to analyze a variety of chemical or biological entities to assist with the drug-discovery pipeline.

TenAces will develop an AI platform to help identify protein interactions that naturally occur in the body to assist with targeted protein degradation.